CD4 and HIV-1 infection: Heterozygotic individuals are not protected against HIV-1 infection but, in most cohort studies, they have been found to have lower viral loads, slower decrease in the CD4+ T cell count and slower progression to AIDS by an additional 2–3 years when compared to CCR5-wild-type individuals (26–29).